These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 28843110)

  • 21. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Schäfer P; Hinke A; Zander AR
    Br J Haematol; 2001 Jun; 113(4):1060-71. PubMed ID: 11442503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the shedding of three β-herpesviruses DNA in Polish patients subjected to allogeneic hematopoietic stem cell transplantation: Six-year follow up.
    Dzieciatkowski T; Tomaszewska A; Przybylski M; Rusicka P; Basak GW; Jedrzejczak WW; Wroblewska M; Halaburda K
    J Clin Virol; 2016 Mar; 76():30-5. PubMed ID: 26809130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Baek JH; Kim JG; Suh JS; Lee KB
    Transplantation; 2006 Jan; 81(1):101-8. PubMed ID: 16421484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
    Marchesi F; Pimpinelli F; Di Domenico EG; Renzi D; Gallo MT; Regazzo G; Rizzo MG; Gumenyuk S; Toma L; Marino M; Cordone I; Cantonetti M; Liberati AM; Montanaro M; Ceribelli A; Prignano G; Palombi F; Romano A; Papa E; Pisani F; Spadea A; Arcese W; Ensoli F; Mengarelli A
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
    Hammerstrom AE; Lombardi LR; Pingali SR; Rondon G; Chen J; Milton DR; Chemaly RF; Champlin RE; Gulbis A; Ciurea SO
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):353-358. PubMed ID: 28986189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
    Pasvolsky O; Bassett RL; Ghanem S; Cuglievan B; Tewari P; Hosing C; Srour S; Ramdial J; Mahadeo KM; Khazal S; Petropoulos D; Popat U; Qazilbash M; Kebriaei P; Champlin R; Shpall EJ; Nieto Y
    BMC Cancer; 2023 Dec; 23(1):1258. PubMed ID: 38124057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expansion of effector memory Vδ2
    Huang Y; Jiang C; Zhu J; Lin L; Mao M; Yin T; Cai G
    Front Immunol; 2024; 15():1397483. PubMed ID: 38915409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma.
    Fassas AB; Bolaños-Meade J; Buddharaju LN; Rapoport A; Cottler-Fox M; Chen T; Lovchik JC; Cross A; Tricot G
    Br J Haematol; 2001 Jan; 112(1):237-41. PubMed ID: 11167810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
    George B; Kerridge IH; Gilroy N; Huang G; Hertzberg MS; Bradstock KF; Gottlieb DJ
    Transpl Infect Dis; 2012 Apr; 14(2):141-8. PubMed ID: 22283838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
    Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
    Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
    Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.